Tarceva’s effect may be part of a stress response to cancer cells that causes them to get stemlike properties, Cheresh said. “We’re pushing these cells into a corner,” Cheresh said. And the more the cancer has mutated to resist the therapy, the more effective Velcade will be. It doesn’t make sense to give Velcade before the resistance has developed. Timing is important for the therapy to have maximum effect, Cheresh said. That suggested the clinical trial’s approach, which uses the evolution of drug resistance as a weapon against the cancer. However, the study found that these cells selectively resist a class of cancer drugs that includes Tarceva. Previous studies had suggested that cancer stem cells employ a general drug resistance mechanism. David Cheresh was its senior author and Laetitia Seguin was its first author. The new study was published online Sunday in the journal Nature Cell Biology. Patients will be tested for tumor cells and DNA circulating in the blood, which will indicate how they are responding. Tarceva is used to combat non-small cell lung cancer and some pancreatic cancers.įor the upcoming clinical trial, all patients will get the Velcade-Tarceva combo there will be no placebo, Husain said. But in lab studies, it also appears to re-sensitize cancer cells that had become resistant to Tarceva, or erlotinib. ![]() Velcade, or bortezomib, is approved to treat relapsed multiple myeloma. For more information about the trial, call (858) 822-5182. Hatim Husain, an author of the study who is designing the clinical trial. This quick start is possible because the drug is currently on the market, said Dr. Researchers at UCSD Moores Cancer Center said they plan to start a clinical trial to test the use of Velcade for lung cancer in about six months. Some drug-resistant cancers of the lung, pancreas and breast might be made vulnerable again by treating them with a medication already approved for another type of cancer, according to a new study led by scientists at UC San Diego.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |